Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Update

Hoth Therapeutics, Inc. (NASDAQ:HOTH) saw a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 326,500 shares, a drop of 50.5% from the January 15th total of 659,200 shares. Based on an average daily volume of 8,520,000 shares, the short-interest ratio is presently 0.0 days. Currently, 4.8% of the company’s shares are sold short.

Hoth Therapeutics Price Performance

HOTH opened at $1.13 on Friday. Hoth Therapeutics has a 1 year low of $0.58 and a 1 year high of $3.80. The company’s 50 day simple moving average is $1.15 and its 200 day simple moving average is $0.94.

Hoth Therapeutics (NASDAQ:HOTH) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.01). As a group, sell-side analysts anticipate that Hoth Therapeutics will post -1.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

HOTH has been the subject of a number of analyst reports. D. Boral Capital reissued a “buy” rating and issued a $5.00 price objective on shares of Hoth Therapeutics in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Hoth Therapeutics in a research note on Thursday, January 23rd.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned 0.47% of Hoth Therapeutics at the end of the most recent quarter. 7.08% of the stock is owned by institutional investors and hedge funds.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.